Combined modality treatments in pancreatic cancer

被引：10

作者：

Lombardi, Lucia ^{[1
]}

Troiano, Michele ^{[2
]}

Silvestris, Nicola ^{[3
]}

Nanni, Luciano ^{[1
]}

Latiano, Tiziana Pia ^{[1
]}

Di Maggio, Gabriele ^{[1
]}

Cinieri, Saverio ^{[4
]}

Di Sebastiano, Pierluigi ^{[5
]}

Colucci, Giuseppe ^{[3
]}

Maiello, Evaristo ^{[1
]}

机构：

[1] IRCCS Casa Sollievo Sofferenza, Oncol Unit, San Giovanni Rotondo, FG, Italy

[2] IRCCS Casa Sollievo Sofferenza, Radiat Therapy Unit, San Giovanni Rotondo, FG, Italy

[3] Natl Canc Inst Giovanni Paolo II, Med & Expt Oncol Unit, Bari, Italy

[4] Perrino Hosp, Med Oncol Unit, Brindisi, Italy

[5] IRCCS Casa Sollievo Sofferenza, Surg Unit, San Giovanni Rotondo, FG, Italy

来源：

EXPERT OPINION ON THERAPEUTIC TARGETS | 2012年 / 16卷

关键词：

adjuvant therapy; chemoradiotherapy; neoadjuvant therapy; pancreatic cancer; GEMCITABINE-BASED CHEMORADIATION; PHASE-III TRIAL; RESECTABLE ADENOCARCINOMA; SURGICAL RESECTION; PREOPERATIVE CHEMORADIATION; NEOADJUVANT THERAPY; RADIATION-THERAPY; CHEMOTHERAPY; CISPLATIN; CHEMORADIOTHERAPY;

D O I：

10.1517/14728222.2012.662959

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Of all the carcinomas, pancreatic carcinoma (PC) has the highest mortality rate, with a 1- and 5-year survival rate of 25% and less than 5% respectively. This is regardless of the stage at diagnosis. Areas covered: In this review relevant literature assessing the evidence regarding preoperative and adjuvant chemoradiotherapy (CRT) is discussed. Furthermore, new therapeutic approaches are summarized, while the future direction regarding the multimodality approach to PC is also discussed. Expert opinion: The role of combined-modality therapy for PC is continuously evolving. There have been several recent developments, as well as the completion of major, multi-institutional clinical trials. One of the challenges for the busy clinician is to appreciate the variation in staging, surgical expertise, and application of either definitive CRT or neo-adjuvant CRT for local and/or borderline disease.

引用

页码：S71 / S81

页数：11

共 50 条

[31] Combined modality treatment for rectal cancer
Zhu, AX
Willett, CG
[J]. SEMINARS IN ONCOLOGY, 2005, 32 (01) : 103 - 112
[32] Combined modality therapy for esophageal cancer
Minsky, BD
[J]. SEMINARS IN ONCOLOGY, 2003, 30 (04) : 46 - 55
[33] Combined modality therapy for esophageal cancer
Blanke, CD
Choy, H
Leach, SD
[J]. SEMINARS IN RADIATION ONCOLOGY, 1997, 7 (03) : 15 - 23
[34] RATIONALE OF COMBINED MODALITY THERAPY FOR CANCER
MARTIN, DS
FUGMANN, R
STOLFI, R
HAYWORTH, P
[J]. CANCER CHEMOTHERAPY REPORTS PART 2 SUPPLEMENT, 1974, 4 (01): : 13 - 24
[35] COMBINED MODALITY THERAPY OF GYNECOLOGIC CANCER
BRADY, LW
[J]. CANCER, 1975, 35 (01) : 76 - 83
[36] Combined modality treatment for esophageal cancer
Tordiglione, M
Kalli, M
Vavassori, V
Luraghi, R
[J]. TUMORI JOURNAL, 1998, 84 (02): : 252 - 258
[37] Combined Modality Therapy for Rectal Cancer
Patel, Sagar A.
Ryan, David P.
Hong, Theodore S.
[J]. CANCER JOURNAL, 2016, 22 (03): : 211 - 217
[38] Combined modality treatment of oesophageal cancer
Stahl, M.
Ruhstaller, T.
[J]. INTERNIST, 2014, 55 (01): : 7 - +
[39] Cervical cancer: Combined modality therapy
Grigsby, PW
[J]. CANCER JOURNAL, 2001, 7 : S47 - S50
[40] Combined Modality Therapy for Rectal Cancer
Minsky, Bruce D.
Roeedel, Claus
Valentini, Vincenzo
[J]. CANCER JOURNAL, 2010, 16 (03): : 253 - 261

← 1 2 3 4 5 →